NASDAQ : IMNN
Imunon, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.11M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.11M |
| Enterprise Value | 6.09M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.61M |
| Shares Outstanding | 5.61M |
| Shares Change (YoY) | +217.32% |
| Shares Change (QoQ) | +4.05% |
| Owned by Insiders (%) | 6.64% |
| Owned by Institutions (%) | 5.68% |
| Float | 5.24M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.19 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.82 |
| Quick Ratio | 1.44 |
| Debt / Equity | 1.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -191.99 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -429.72% |
| Return on Assets (ROA) | -77.99% |
| Return on Invested Capital (ROIC) | -116.73% |
| Return on Capital Employed (ROCE) | -145.30% |
| Weighted Average Cost of Capital (WACC) | 6.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$736,658 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.08 |
| 52-Week Price Change | -80.04% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 2.24 |
| Relative Strength Index (RSI) | 36.04 |
| Average Volume (20 Days) | 121,837 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 62,366 |
| Short Previous Month | 173,197 |
| Short % of Shares Out | 1.11% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 0.54 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -409,917 |
| Operating Income | -14.84M |
| Pretax Income | -14.72M |
| Net Income | -14.73M |
| EBITDA | -14.55M |
| EBIT | -14.84M |
| Earnings Per Share (EPS) | -$3.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.86M |
| Total Debt | 7.85M |
| Net Cash | -980,914 |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | 4.19M |
| Book Value Per Share | 0.42 |
| Working Capital | 3.91M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.11M |
| Capital Expenditures | -72,669 |
| Depreciation & Amortization | 290,218 |
| Net Borrowing | 7.03M |
| Free Cash Flow | -15.18M |
| FCF Per Share | -$2.71 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -217.32% |
| Shareholder Yield | n/a |
| Earnings Yield | -392.21% |
| FCF Yield | -297.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.00 |
| Price Target Difference | 1,768.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 7, 2025 |
| Split Type | Forward |
| Split Ratio | 1.15:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |